Genmab — September 2025
-
RYBREVANT
(amivantamab-vmjw) plus LAZCLUZE (lazertinib) offers unmatched survival benefit in a chemotherapy-free regimen, reducing treatment resistance vs osimertinib in first-line EGFR-mutated NSCLC https://www.jnj.com/media-center/press-releases/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-offers-unmatched-survival-benefit-in-a-chemotherapy-free-regimen-reducing-treatment-resistance-vs-osimertinib-in-first-line-egfr-mutated-nsclc -
Ugens danske Vindere & Tabere: Genmab, Ørsted og Norden https://proinvestor.com/investornyt/1358883/ugens-danske-vindere-amp-tabere-genmab-oslashrsted-og-norden
-
En del om Rina-S ved 18:17 og 30:00 https://uniteforher.com/herlibrary/video/updates-in-ovarian-cancer/
-
Genmab: Partner har lovende resultater med middel mod lungekræft
8:24
Genmabs partner Johnson & Johnson har offentliggjort lovende resultater med sit lungekræftmiddel Rybrevant som førstebehandling i kombination med lægemidlet Lazcluse. Kombinationen tegner bedre for patienternes overlevelse end lægemidlet Osimertinib.Det fremgår af en meddelelse fra Johnson & Johnson.
Genmab modtager høje encifrede og op til tocifrede royalties fra Johnson & Johnsons salg af Rybrevant, der solgte for 320 mio
-
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC https://www.nejm.org/doi/full/10.1056/NEJMoa2503001
-
Novo og europæiske sundhedskollegaer holdes nede af advarsel fra Morgan Stanleyhttps://proinvestor.com/investornyt/1359075/novo-og-europaeiske-sundhedskollegaer-holdes-nede-af-advarsel-fra-morgan-stanley
-
Data published in The New England Journal of Medicine demonstrate RYBREVANT
(amivantamab-vmjw) plus LAZCLUZE (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer
September 8, 2025 https://innovativemedicine.jnj.com/us/news-center/oncology/data-published-in-the-new-england-journal-of-medicine-demonstrate-rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-is-re-setting-survival-expectations-in-first-line-egfr-mutated-lung-cancer -
Summit nåede ikke endpoint i OS med deres vegf x pd-1 i NSCLC https://www.investors.com/news/technology/summit-therapeutics-stock-pd-1-vegf-lung-cancer-treatment/?src=A00220
-
in 5minutes Sep 9, 2025 7:45 AM EDT
Morgan Stanley 23rd Annual Global Healthcare Conference https://ir.genmab.com/events-presentations -
JOB ALERT: Genmab is #hiring a Director, Global Marketing Solid Tumors! https://x.com/BioNJ_Org/status/1965430203003375745
-
Solsen 21:40 nej vel. tror ikke man har tænkt sig at reengineere eksisterende stoffer. Men Jan taler om den unikke linker i Rina-s og deres store forventninger / erfaringer med immune aktivering i aca og Gen 1042. Så siger han at de vil udforske en BsADC med duobody+Rina-s linker(og payload) + 4-1bb stimulering ? Det viser da mega høj tiltro til egne stoffer, hvis det er det han tænker
-
I think he spoke about –developing other ADC’s with the ProfoundBio payload and Hydrophilic linker technology – developing Rina-S for other targets (we knew about non-small cell lung cancer, but they are looking at others and they believe this could be a drug for multiple cancers, but don’t want to disclose which ones for competitive reasons) and
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind